OSRX Expands Medication Sizes and Introduces Direct-to-Patient Post-Op Kits

OSRX is expanding its pharmaceutical offerings with new medication sizes and direct-to-patient post-op kits. These additions are designed to streamline workflows for eye care professionals while improving patient convenience and experience.

Expanded Medication Sizes for Efficiency and Cost-Effectiveness

Among the newly available options, OSRX now provides Tropicamide 1% + Phenylephrine 2.5% in a 10mL fill size, in addition to the existing 2mL option. This larger volume is intended to help eye care practices:

       • Reduce frequent reordering

       • Minimize medical waste

       • Optimize costs while maintaining high-quality patient care

Dr. Paul Mann of Mann Eye Institute praised OSRX’s dilation drops, stating, "When I started prescribing OSRX’s Tropicamide/Phenylephrine HCl dilation drops over two years ago, our patient process completely transformed. The medications provide our patients with what they need, and as an added benefit, using OSRX has streamlined our procedures, enabling us to focus even more on what we do best: providing exceptional patient care."

Additionally, the company is offering an expanded 5mL option of Brimonidine 0.1% + Dorzolamide 2%, a combination therapy designed for enhanced convenience and cost management. This medication is available for both direct-to-patient shipping and office stock, making it an efficient option for prescribers.

Direct-to-Patient Post-Op Kits Reduce Logistical Burdens

OSRX is also introducing exclusive direct-to-patient post-op kits in collaboration with a third-party manufacturer. These kits are designed to alleviate logistical challenges for eye care practices while enhancing the post-surgical patient experience. Each kit includes:

       • A durable post-op bag

       • Solar Shield sunglasses

       • A polycarbonate eye shield and tape

By offering these kits directly to patients, OSRX aims to support clinics in delivering seamless postoperative care with minimal administrative burden.

Conclusion

With these expanded medication sizes and the introduction of direct-to-patient post-op kits, OSRX is positioning itself as a key player in optimizing ophthalmic care. These updates not only enhance efficiency for eye care professionals but also contribute to better patient outcomes by providing accessible, high-quality treatment solutions.